UBS Maintains Neutral on RXO, Raises Price Target to $26
UBS analyst Thomas Wadewitz maintains RXO (NYSE: RXO ) with a Neutral and raises the price target from $22 to $26.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.